Foresee Pharmaceuticals Email Formats
Biotechnology Research • 
Nangang District, Taipei City, Taiwan, Province of China • 21-50 Employees
Foresee Pharmaceuticals Email Formats
Foresee Pharmaceuticals uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@foreseepharma.com), used 73.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@foreseepharma.com | 73.7% |
{first initial}.{last name} | j.doe@foreseepharma.com | 26.3% |
Key Contacts at Foresee Pharmaceuticals
Scott Johnson
Senior Director And Head Of Quality Assurance
Susan Whitaker
Senior Director Clinical Operations
Allison Mccourt
Director, Alliance Management
Yuhua Li
Co-Founder & Chief Technology Officer
Andrew Gibbons
Associate Director Of Clinical And Commercial Supply Chain
Nancy Liu
Senior Director Of Analytical Development And Qc
Qin Ren
Senior Director Of Cmc Operations
Chi-Feng Yen
Sr. Director Of Api Operations
Yunhai Xiao
Director Of Analytical Development And Qc
Benjamin Chien
Ceo
Company overview
| Headquarters | No.19-3, Sanchong Rd., Nangang Dist., Taipei City, Taiwan, 9F-2, Taipei, 115, TW |
| Phone number | +88613025765860 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Biotechnology, Urology, Neuroscience, Pharmaceuticals, Oncology, Rare Disease, Cardiology/Vascular Diseases, Pulmonary/Respiratory Diseases |
| Founded | 2013 |
| Employees | 21-50 |
About Foresee Pharmaceuticals
Foresee Pharmaceuticals is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (TPEx: 6576). Foresee's R&D efforts are focused on two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable technology with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee's product portfolio includes late and early-stage programs. CAMCEVI 6-month formulation, for the treatment of advanced prostate cancer, is now approved in the U.S., Canada, EU, Taiwan and Israel and launched in the U.S.. Additionally, the U.S. NDA for the 3-month version of CAMCEVI has been submitted. For the second indication of CAMCEVI 42 mg, central precocious puberty (CPP), the Casppian phase 3 clinical study, has been initiated. FP-025, a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, has been investigated in a Phase 2 POC study in allergic asthmatic patients. The study has been completed with positive outcomes, with future development in rare immune-fibrotic diseases. FP-020, a follow-on oral MMP-12 inhibitor, for which a Phase 1 study has been completed, with development targeted in severe asthma, COPD and IBD. FP-045 is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the FuschiA Phase 1b/2 Fanconi Anemia study is currently being initiated, and the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients is in planning with targeted initiation in the fourth quarter of 2024. Building on the compelling biology of ALDH2, and translational data from several Foresee ALDH2 activators, a follow-on candidate from a new series of compounds is being selected for development in metabolic syndrome/healthy weight loss and the broader cardiovascular-renal-metabolic space.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Foresee Pharmaceuticals has 20 employees across 9 departments.
Departments
Number of employees
Funding Data
Explore Foresee Pharmaceuticals's funding history, including investment rounds, total capital raised, and key backers.
Canada
Spain
South Africa
Frequently asked questions
4.8
40,000 users
